Up, up, up: After Allergan offer, would-be buyer Ackman reaps $1.2B in gains

Save

Valeant and partner Bill Ackman may not yet have bagged acquisition target Allergan, but shares have leapt since the takeover team went public with its plans in mid-April, helping push gains for Ackman's hedge fund, Pershing Square Capital Management, to $1.2 billion.